Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zenocort
- Development stage
- Unknown
- Lead developer
- Atro Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Zenocort is an oral corticosteroid tablet developed and marketed by Atro Pharma. It is a small molecule therapeutic that functions as an agonist of the glucocorticoid receptor, mediating potent anti-inflammatory and immunosuppressive effects. The medication is indicated for the management of various inflammatory conditions and autoimmune disorders. Zenocort is part of Atro Pharma's portfolio of formulated generic products and is designed to provide effective therapeutic benefits with a focus on minimizing the side effects typically associated with traditional corticosteroid therapy. It has received regulatory approval and is currently available in tablet form for oral administration.
- Brand names
- Zenocort
- Other names
- Zenocort Tablet
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on Zenocort.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zenocort.